-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Pharmaceutical network October 15th, October 14th, CDE official website data show that Lizhu, Qilu respectively declared the injection of Voliconazole 4 types of imitation listing applications, were accepted.
voliconazole for the whole body with antifygal drug TOP1 varieties, leading Pfizer in the domestic generic drug under the constant impact of the market share of only 40%.
Figure 1: Lizhu, Qilu declared the registration of voliconazole for injection Source: CDE official website Figure 2: 2019 Voliconazole's enterprise competition pattern Source: Minet China's public medical institutions terminal competition pattern Minet data show that in China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) terminal antifellar drug market, Volicanto with more than 5 billion yuan of sales.
In terms of dosage form, injections accounted for 55.59 percent, tablets for 37.43 percent and capsules for 6.98 percent, and Pfizer, the leader, has lost half of its market share since 2015, falling from 49.98 percent to 45.70 percent in 2019.
figure 3: Currently obtained the injection of Voliconazole production approval of the enterprise source: one-click search currently obtained the injection of Voliconazole production approval of the enterprise in addition to Puqiang (Pfizer's company), there are Zhuhai Ebon Pharmaceuticals, Jincheng Hais Pharmaceuticals, Sichuan Meida Kang Huakang Pharmaceuticals and Lizhu Group Lizhu Pharmaceutical Factory, there is currently no enterprise evaluation.
Lizhu this declaration of the big probability is the new specifications of products, in addition to Qilu new joined the war situation, Fu'an Pharmaceutical Group Yantai only Chu Pharmaceuticals on October 10 declared the four types of imitation listing applications have been accepted, and the current listing applications involving enterprises such as Wuhan Qirui Pharmaceuticals, Hainan Beite Pharmaceuticals and Nanjing Sonic Dongyuan Pharmaceuticals.
source: MiNet database, CDE official website.
